Int J Radiat Oncol Biol Phys 1995,32(1):3–12.PubMedCrossRef 9. Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A: What dose of external-beam

radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 2007, 68:682–689.PubMedCentralPubMedCrossRef 10. Hanks GE, Hanlon AL, Epstein B, Horwitz EM: Dose response in prostate cancer with 8–12 years’ follow-up. Int J Radiat Oncol Biol Phys 2002, 54:427–435.PubMedCrossRef 11. Jacob R, Hanlon AL, Horwitz Erastin concentration EM, Movsas B, Uzzo RG, Pollack A: The relationship of increasing radiotherapy dose to reduced distant metastases ad mortality in men with prostate cancer. Cancer 2004, 100:538–543.PubMedCrossRef 12. Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG, Hanks GE: Prostate cancer radiotherapy dose response: an update of the Fox Chase experience. J Urol 2004, 171:1132–1136.PubMedCrossRef 13. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H: Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006,176(4 Pt 1):1415–1419.PubMedCrossRef

14. Michalski JM, Bae K, Roach M, Markoe AM, Sandler HM, Ryu J, Parliament MB, Straube W, Valicenti RK, Cox JD: Long-term toxicity following 3D conformal YAP-TEAD Inhibitor 1 datasheet radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys 2010, 76:14–22.PubMedCentralPubMedCrossRef 15. De Meerleer GO, Fonteyne VH, Vakaet L, Villeirs GM, Denoyette L, Verbaeys A, Lummen N, De Neve WJ: Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control. Radiother Oncol 2007, 82:160–166.PubMedCrossRef 16. Fonteyne V, Villeirs G, Lumen N, De Meerleer G: Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer. Radiother Oncol 2009, 92:42–47.PubMedCrossRef 17. Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, Hunt M, Greenstein S, Amols H: Ultra-high dose (86.4Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int

J Radiat Oncol Biol Phys 2008, 71:330–337.PubMedCrossRef 18. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA: High-dose intensity modulated radiation Immune system therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002,53(5):1111–1116.PubMedCrossRef 19. Landoni V, Saracino B, Marzi S, Gallucci M, AZD0530 price Petrongari MG, Chianese E, Benassi M, Iaccarino G, Soriani A, Arcangeli G: A study of the effect of setup errors and organ motion on prostate cancer treatment with IMRT. Int J Radiat Oncol Biol Phys 2006, 65:587–594.PubMedCrossRef 20. Mundt AJ, Lujan AE, Rotmensch J, Waggoner SE, Yamada SD, Fleming G, Roeske JC: Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002, 52:1330–1337.PubMedCrossRef 21.